Loading…
Biodesix, Inc. is projected to rise to $31.05 by 2027, a +46% move from its current price of $21.20. BDSX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $20.39 | $21.22 | $22.08 | +0.08% |
| Aug 4 | $20.07 | $21.23 | $22.46 | +0.16% |
| Aug 5 | $19.84 | $21.25 | $22.76 | +0.24% |
| Aug 6 | $19.64 | $21.27 | $23.02 | +0.31% |
| Aug 7 | $19.48 | $21.28 | $23.26 | +0.39% |
| Aug 8 | $19.33 | $21.30 | $23.48 | +0.47% |
| Aug 9 | $19.19 | $21.32 | $23.68 | +0.55% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $19.19 | $21.32 | $23.68 | +0.55% |
| Week 2 | $18.47 | $21.43 | $24.87 | +1.10% |
| Week 3 | $17.97 | $21.55 | $25.85 | +1.66% |
| Week 4 | $17.56 | $21.67 | $26.74 | +2.22% |
| Week 5 | $17.23 | $21.79 | $27.56 | +2.78% |
| Week 6 | $16.94 | $21.91 | $28.34 | +3.34% |
| Week 7 | $16.68 | $22.03 | $29.09 | +3.91% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories.
The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Biodesix, Inc. trades under the ticker BDSX. The current price is $21.39 with a market cap of $221.51M, and it holds a rank of 3595. The current positioning reflects a small-cap company within the healthcare diagnostics space, with the stock price and market cap indicating a niche market focus.
The price outlook, based on the provided year-by-year forecast, shows potential upside over the coming years, beginning with a neutral stance in 2026 and turning bullish in subsequent years as average prices rise.
A major floor 53.6% below — a decisive break under it would weaken the trend.
The nearest floor, 20.7% below — buyers have tended to step in here.
The nearest ceiling, 15.6% above — a clean break opens room to run.
A major ceiling 34.6% above — clearing it would confirm fresh momentum.
Key BDSX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BDSX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $21.23 | Sell | $21.21 | Sell |
| MA 10 | $21.28 | Sell | $21.21 | Sell |
| MA 20 | $21.12 | Buy | $20.90 | Buy |
| MA 50 | $18.74 | Buy | $19.13 | Buy |
| MA 100 | $16.46 | Buy | $16.90 | Buy |
| MA 200 | $12.74 | Buy | $14.78 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.72 | Neutral |
| Stoch RSI (14) | 33.98 | Neutral |
| CCI (20) | 8.53 | Neutral |
| Williams %R (14) | -44.62 | Info |
| MACD (12,26,9) | -0.21 | Sell |
| ROC (12) | 0.95 | Buy |
| Bollinger %B (20,2) | 0.53 | Neutral |
| Stochastic %K (14) | 55.38 | Neutral |
| TRIX (15) | 0.63 | Buy |
| Awesome (5,34) | 0.88 | Buy |
| Ultimate (7,14,28) | 49.44 | Neutral |
| Momentum (10) | 1.01 | Buy |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 20.80 | Buy |
| ADX (14) | 15.45 | Neutral |
| ATR (14) | 0.72 | Info |
The 30-day technical picture is bullish. RSI14 sits at 60, and the price is trading above the SMA50 of $17.81 and the SMA200 of $12.25, suggesting an uptrend. Key levels include a support at $14.80 and a resistance at $24.50, framing a positive momentum zone.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.46 | $21.20 | $29.88 | 0% | Neutral | |
| $23.75 | $31.05 | $43.50 | +46% | Bullish | |
| $26.29 | $35.89 | $52.92 | +69% | Bullish | |
| $26.78 | $37.91 | $58.15 | +79% | Bullish | |
| $26.60 | $38.88 | $61.64 | +83% | Bullish | |
| $28.24 | $42.53 | $69.36 | +101% | Bullish | |
| $27.97 | $43.31 | $72.43 | +104% | Bullish | |
| $32.45 | $51.60 | $88.28 | +143% | Bullish | |
| $41.02 | $66.90 | $116.87 | +216% | Bullish | |
| $42.52 | $71.05 | $126.53 | +235% | Bullish | |
| $53.18 | $99.61 | $192.08 | +370% | Bullish | |
| $88.07 | $195.71 | $422.69 | +823% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $5.46 | $21.20 | $25.36 | +0.00% |
| September 2026 | $18.27 | $21.90 | $27.19 | +3.30% |
| October 2026 | $18.80 | $22.77 | $28.71 | +3.97% |
| November 2026 | $18.37 | $22.43 | $28.63 | -1.48% |
| December 2026 | $18.82 | $23.15 | $29.88 | +3.22% |
Click any year to see its month-by-month BDSX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BDSX is projected to trade between $5.46 and $29.88, averaging $21.20 — a potential gain of 0% from today's $21.20. Price action looks broadly range-bound.
Biodesix, Inc.'s 2027 outlook centres on $31.05, within a $23.75 to $43.50 range. That is up +46% on the projected 2026 average. That marks a +46% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, BDSX could reach as high as $52.92, with a base case around $35.89 and support toward $26.29 — roughly +69% from $21.20. Momentum favours further upside here.
Expect BDSX to range from $26.78 to $58.15 through 2029. The $37.91 average target implies a +79% move from current prices. That is up +6% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The BDSX price prediction for 2030 points to an average of $38.88 (low $26.60, high $61.64) — a potential gain of +83% on today's $21.20. Momentum favours further upside here.
In 2031, BDSX is projected to trade between $28.24 and $69.36, averaging $42.53 — a potential gain of +101% from today's $21.20. That is up +9% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Biodesix, Inc.'s 2032 outlook centres on $43.31, within a $27.97 to $72.43 range. That is up +2% on the projected 2031 average. That marks a +104% change versus current levels. Momentum favours further upside here.
By 2033, BDSX could reach as high as $88.28, with a base case around $51.60 and support toward $32.45 — roughly +143% from $21.20. Buyers look set to stay in control over this stretch.
Expect BDSX to range from $41.02 to $116.87 through 2034. The $66.90 average target implies a +216% move from current prices. That is up +30% on the projected 2033 average. Momentum favours further upside here.
The BDSX price prediction for 2035 points to an average of $71.05 (low $42.52, high $126.53) — a potential gain of +235% on today's $21.20. Buyers look set to stay in control over this stretch.
In 2040, BDSX is projected to trade between $53.18 and $192.08, averaging $99.61 — a potential gain of +370% from today's $21.20. That is up +40% on the projected 2035 average. Momentum favours further upside here.
Biodesix, Inc.'s 2050 outlook centres on $195.71, within a $88.07 to $422.69 range. That is up +96% on the projected 2040 average. That marks a +823% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in BDSX today (≈ 47.169811 BDSX) could be worth
$9,231.68
+$8,231.68 (+823%) by 2050 · US Dollar
Based on the average projected BDSX price of $195.71 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BDSXwould be worth at today's price.
$1,000 invested in BDSX on Jul 31, 2025 (≈ 142.045455 BDSX) would be worth
$3,011.36
+$2,011.36 (+201.1%) today · 3.01× · US Dollar
Based on a BDSX entry price of $7.04 vs. today's $21.2.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $22 | $963.64 | -3.6% |
| 1 month ago | $24.5 | $865.31 | -13.5% |
| 3 months ago | $11.08 | $1,913.36 | +91.3% |
| 6 months ago | $10.29 | $2,060.25 | +106.0% |
| 1 year ago | $7.04 | $3,011.36 | +201.1% |
| All time (5.0y) ago | $184.2 | $115.09 | -88.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BDSX forecast.
Our base-case forecast reaches $42.00 around 2031.
Implied market cap at $42.00: $434.94M
The multi-year forecast outlines a path of growth with steadily rising average prices and increasing ROI after 2026. In 2026 the avg is $21.39 with a neutral sentiment and a min of $5.46 and max of $30.62. From 2027 onward, the average price climbs to $30.22 (ROI 41.3%), then to $33.80 (ROI 58%) in 2028 and $35.98 (ROI 68.2%) in 2029.
The 2030 forecast shows an average of $35.24 (ROI 64.7%), followed by further gains through 2031 at $36.70 (ROI 71.6%) and 2032 at $36.83 (ROI 72.2%). The 2033 average reaches $41.19 (ROI 92.5%), and 2034 climbs to $54.42 (ROI 154.4%), with a max of $99.09. In 2035 the avg is $59.40 (ROI 177.7%), and the trajectory continues to 2040 with an avg of $72.71 (ROI 239.9%), culminating in 2050 with an avg of $146.06 (ROI 582.9%) and a max of $333.73.
These figures indicate significant upside potential but are estimates, not guarantees, and depend on market conditions and other factors.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $35.24 with a min of $23.26 and a max of $57.77, and a forecast ROI of 64.7% with a bullish sentiment.
Forecasts show rising average values and positive ROI beginning in 2027 (avg $30.22, ROI 41.3%) and continuing to higher levels through 2050, though 2026 is neutral and actual results may vary.
Yes. The 2034 max is $99.09 and the 2035 max is $110.43, so surpassing $100 is possible by 2035 in the max scenario.
Current price is $21.39 and market cap is $221.51M; the stock is ranked 3595.
The 30-day picture is bullish, with RSI14 at 60, SMA50 at $17.81, SMA200 at $12.25, a support level of $14.80, a resistance at $24.50, and a 30-day range of $15.94 to $28.71, plus an annualized volatility of 90%.
Biodesix, Inc. Community Discussion
0Share your Biodesix, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.